-+ 0.00%
-+ 0.00%
-+ 0.00%

Biovica Signs US Commercial Deal for Blood-based Biomarker Test

MT Newswires·12/15/2025 05:06:35
Listen to the news
05:06 AM EST, 12/15/2025 (MT Newswires) -- Biovica International (BIOVIC-B.ST) secured another reference institution in the US for its blood-based biomarker test as it signed a commercial agreement with an unnamed comprehensive cancer center. The Sweden-based blood-based cancer monitoring company said Monday the client bill deal means that clinicians at the "leading US NCI-designated" center will be able to order its DiviTum TKa for clinical use in breast cancer in a streamlined process.